Nesyrgy (Amlodipine Besilate, Nebivolol Hydrochloride)

Amlodipine besilate blocks L‑type calcium channels in vascular smooth muscle, leading to arterial relaxation and reduced peripheral resistance. Nebivolol hydrochloride selectively blocks β1‑adrenergic receptors, decreasing heart rate and contractility, while also stimulating endothelial nitric‑oxide production, which further dilates blood vessels. The dual action results in a synergistic reduction of systemic blood pressure.

The dosage of Nesyrgy is individualized by the prescribing healthcare professional based on the patient’s blood‑pressure profile, age, renal and hepatic function, and concomitant medications. Physicians determine the appropriate strength and frequency, and patients should follow the prescribed regimen without making any changes on their own.

Safety of Nesyrgy in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To place an order, submit an enquiry on the Nesyrgy product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements if applicable), and assists with import documentation.

Compared with monotherapy agents such as amlodipine alone or a standalone β‑blocker, Nesyrgy offers combined vasodilatory and β1‑blocking effects in a single tablet, which can improve blood‑pressure control and simplify regimens. It may be preferred when patients need both arterial dilation and heart‑rate reduction, whereas alternatives like ACE‑inhibitor or ARB combinations target different pathways.

Store Nesyrgy tablets at ambient temperature, preferably below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments, which could affect tablet integrity.

Nesyrgy is taken orally, usually once daily. The tablet should be swallowed whole with a glass of water and can be taken with or without food. Patients should follow the dosing schedule prescribed by their clinician and should not split, crush, or chew the tablet unless specifically instructed.

The most serious adverse events to monitor include severe hypotension, marked bradycardia or heart block, angioedema, and significant hepatic dysfunction. If any of these occur—such as sudden dizziness, fainting, rapid weight gain, yellowing of the skin or eyes, or swelling of the face and throat—medical attention should be sought immediately.

Nesyrgy is contraindicated in patients with known hypersensitivity to amlodipine, nebivolol, or any excipients, as well as those with severe hypotension, cardiogenic shock, or advanced heart block without a pacemaker. Caution is also advised for individuals with severe hepatic impairment, aortic stenosis, or uncontrolled heart failure. Clinicians should evaluate each patient’s medical history before prescribing.